INTRODUCTION: In Serbia, there is a significant number of @entity1 suffering of @entity2258 . @entity1 aged 65 years or older, immunocompromised @entity1 , @entity1 with co-morbidities, such as @entity1030 and @entity712 , are at the highest risk for developing @entity2258 . Most of the @entity1 are treated empirically, although it is often overlooked that @entity328 can be resistant to the used antibiotics. The treatment costs of such inpatients and outpatients are very high. In Serbia, immunization of @entity1 at risk to develop the diseases caused by @entity328 is carried out using pneumococcus polysaccharide vaccine according to clinical indications. The exact number of immunized @entity1 and the total number of registered @entity1 are still unknown, but it is certain of being unjustifiably low. OBJECTIVE: The goal of the study was to investigate, during a one-year period, the number and basic characteristics of @entity1 hospitably treated for @entity55 , the type of cause of the infection, applied antibiotic medications, duration and costs of hospital treatment at the Institute for @entity358 and @entity378 of the Clinical Centre of Serbia in Belgrade. METHOD: We retrospectively analyzed the medical records of @entity1 with @entity55 treated at the Institute for @entity358 and @entity378 of the Clinical Centre of Serbia in Belgrade during 2006. RESULTS: During the observed one-year period, 290 @entity1 underwent hospital treatment, of whom the cause of the infection was confirmed in 116 (40%). The average duration of hospitalization was 12 days, with treatment cost of 32,031.74 RSD (402.42 EUR) per @entity1 . The treatment cost per @entity1 including general and intensive care was 18,290.01 RSD (229.78 EUR). The distribution cost of Pneumo 23 vaccine in Serbia, without purchase tax, was 746.90 RSD (9.38 EUR). CONCLUSION: @entity2258 is a significant medical and economic problem for the healthcare system of Serbia. The use of antipneumococcal vaccination can be useful in decreasing the overall treatment costs related to @entity7706 .

[Economic aspects of hospitaly treated XXXX and the results of Pneumo 23 vaccine use in Serbia].

@entity1 :: ('9606', 'Species') :: ['Persons', 'patients', 'patient', 'persons'] @entity712 :: ('MESH:D006333', 'Disease') :: ['congestive heart failure'] @entity7706 :: ('MESH:D011008', 'Disease') :: ['pneumococcal infection'] @entity55 :: ('MESH:D011014', 'Disease') :: ['pneumonia'] @entity358 :: ('MESH:D008171', 'Disease') :: ['Lung Diseases'] @entity1030 :: ('MESH:D029424', 'Disease') :: ['chronic obstructive lung disease'] @entity2258 :: ('MESH:D011018', 'Disease') :: ['pneumococcal pneumonia', 'Pneumococcal pneumonia'] @entity378 :: ('MESH:D014376', 'Disease') :: ['Tuberculosis'] @entity328 :: ('1313', 'Species') :: ['Streptococcus pneumoniae']
@entity2258 :: (MESH:D011018,Disease) :: ['pneumococcal pneumonia']
